Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Assets (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Assets for 11 consecutive years, with $296.4 million as the latest value for Q4 2025.

  • Quarterly Assets fell 31.86% to $296.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $296.4 million through Dec 2025, down 31.86% year-over-year, with the annual reading at $296.4 million for FY2025, 31.86% down from the prior year.
  • Assets for Q4 2025 was $296.4 million at Cartesian Therapeutics, down from $372.7 million in the prior quarter.
  • The five-year high for Assets was $455.3 million in Q3 2024, with the low at $106.0 million in Q3 2023.
  • Average Assets over 5 years is $254.9 million, with a median of $184.3 million recorded in 2021.
  • The sharpest move saw Assets plummeted 40.52% in 2023, then skyrocketed 329.41% in 2024.
  • Over 5 years, Assets stood at $159.9 million in 2021, then increased by 3.75% to $165.9 million in 2022, then soared by 83.89% to $305.0 million in 2023, then surged by 42.61% to $435.0 million in 2024, then tumbled by 31.86% to $296.4 million in 2025.
  • According to Business Quant data, Assets over the past three periods came in at $296.4 million, $372.7 million, and $388.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.